Oxford Cancer Biomarkers

Oxford, United Kingdom

Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.

Apr 2023

Venture - Series Unknown

Biopharma Biotechnology Health Care

Top Investors

Longwall Venture NHS England Panacea Capital Esperante Ventures Kwang Dong Pharmaceutical

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Oxford Cancer Biomarkers

Who are Oxford Cancer Biomarkers's investors?

Oxford Cancer Biomarkers's investors include Longwall Venture, NHS England, Panacea Capital, Esperante Ventures, Kwang Dong Pharmaceutical.

Where is Oxford Cancer Biomarkers headquartered?

Oxford Cancer Biomarkers is headquartered in Oxford, United Kingdom.

What does Oxford Cancer Biomarkers do?

Oxford Cancer is developing and commercialising a suite of colorectal cancer biomarker tests to improve the current treatment pathway.

What stage is Oxford Cancer Biomarkers at?

Oxford Cancer Biomarkers is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 3, 2023.

MLA

"Oxford Cancer Biomarkers — Funding & Investors." VCBacked, April 3, 2023, https://www.vcbacked.co/company/oxford-cancer-biomarkers. Accessed July 3, 2026.

APA

VCBacked. (2023). Oxford Cancer Biomarkers — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/oxford-cancer-biomarkers

Wikipedia (cite web)

{{cite web |title=Oxford Cancer Biomarkers — Funding & Investors |url=https://www.vcbacked.co/company/oxford-cancer-biomarkers |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 3, 2023.